How Should Early Gestational Trophoblastic Disease Be Managed?

Kerkmeijer, Linda G.W.; Schink, Julian C.

doi:10.1007/978-0-85729-910-9_26

Cited by 1 publication

(1 citation statement)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…and each of these centres may use a different pathology service and/or hCG assay. A woman’s hCG value can vary depending on the assay used and this introduces a risk that treatment is stopped too early or disease recurrence is missed [ 50 ]. The use of rapid urine pregnancy tests (one-step immunoassay) for measurement of hCGβ in near-patient testing (e.g., emergency departments) may introduce an additional risk of generating a false negative result and lead to delayed diagnosis and adverse patient outcome [ 51 ].…”

Section: Is Centralised Hcg Testing the Solution?mentioning

confidence: 99%

Measurement of Human Chorionic Gonadotrophin in Women with Gestational Trophoblastic Disease

McMahon¹,

Joyce²,

Cuthill³

et al. 2023

Gynecol Obstet Invest

View full text Add to dashboard Cite

Objectives: The objective of this study was to collect information on human chorionic gonadotrophin (hCG) laboratory testing and reporting in women with gestational trophoblastic disease (GTD), to assess the associated challenges, and to offer perspectives on hCG testing harmonisation. Design: Information was collected from laboratories by electronic survey (SurveyMonkey) using a questionnaire designed by members of the European Organisation for the Treatment of Trophoblastic Disease (EOTTD) hCG working party. Participants: The questionnaire was distributed by the EOTTD board to member laboratories and their associated scientists who work within the GTD field. Setting: The questionnaire was distributed and accessed via an online platform. Methods: The questionnaire consisted of 5 main sections. These included methods used for hCG testing, quality procedures, reporting of results, laboratory operational aspects, and non-GTD testing capability. In addition to reporting these survey results, examples of case scenarios which illustrate the difficulties faced by laboratories providing hCG measurement for GTD patient management were described. The benefits and challenges of using centralised versus non-centralised hCG testing were discussed alongside the utilisation of regression curves for management of GTD patients. Results: Information from the survey was collated and presented for each section and showed huge variability in responses across laboratories even for those using the same hCG testing platforms. An educational example was presented, highlighting the consequence of using inappropriate hCG assays on clinical patient management (Educational Example A), along with an example of biotin interference (Educational Example B) and an example of high-dose hook effect (Educational Example C), demonstrating the importance of knowing the limitations of hCG tests. The merits of centralised versus non-centralised hCG testing and use of hCG regression curves to aid patient management were discussed. Limitations: To ensure the survey was completed by laboratories providing hCG testing for GTD management, the questionnaire was distributed by the EOTTD board. It was assumed the EOTTD board held the correct laboratory contact, and that the questionnaire was completed by a scientist with in-depth knowledge of laboratory procedures. Conclusions: The hCG survey highlighted a lack of harmonisation of hCG testing across laboratories. Healthcare professionals involved in the management of women with GTD should be aware of this limitation. Further work is needed to ensure an appropriate, quality-assured laboratory service is available for hCG monitoring in women with GTD.

show abstract

Section: Is Centralised Hcg Testing the Solution?mentioning

confidence: 99%